FDA Examines Testosterone Therapy as Use Among Menopausal Women Rises

Testosterone has traditionally been associated with men, but its role in women’s health is receiving renewed attention as more menopausal women explore hormone therapy for symptoms affecting their sexual health and quality of life.

The US Food and Drug Administration (FDA) is examining the scientific evidence surrounding testosterone use in menopausal women, including its potential benefits, risks, dosing and long-term safety. The agency’s public meeting comes as doctors, researchers and patients continue to debate whether women should have access to a testosterone treatment specifically designed and approved for female use.

The discussion is particularly relevant because there is currently no FDA-approved testosterone product specifically indicated for women. Some physicians nevertheless prescribe testosterone off-label, often using formulations originally approved for men at substantially lower doses.

Why are women using testosterone?

Testosterone is produced naturally by women as well as men, although women generally have much lower levels. Testosterone levels also change over the course of a woman’s life.

Interest in testosterone therapy has increased among women experiencing menopause, particularly those dealing with persistent problems with sexual desire.

One condition frequently discussed in connection with testosterone is hypoactive sexual desire disorder, or HSDD. The condition involves persistently low sexual desire that causes personal distress and cannot be adequately explained by other factors.

Some women who have used testosterone report improvements in sexual desire and satisfaction. Submissions collected by the FDA before its meeting also included women describing perceived improvements in energy and overall quality of life.

These personal experiences have contributed to growing interest in testosterone. However, individual reports do not establish that a treatment is safe or effective for everyone.

What does the scientific evidence show?

The evidence for testosterone in menopausal women is not equally strong across all the claims made about the hormone.

Medical specialists have generally identified sexual function, particularly HSDD, as the area in which evidence is most established.

By contrast, claims that testosterone reliably improves muscle mass, bone density, mood, cognition or general wellbeing remain less firmly supported.

That distinction is important because testosterone has increasingly been discussed on social media as a potential treatment for a broad range of menopause-related concerns. Researchers and clinicians have emphasized that evidence for one symptom does not automatically demonstrate benefits for other health outcomes.

The FDA’s review therefore provides an opportunity to separate established evidence from emerging research and anecdotal experiences.

Why does the lack of a female-specific product matter?

Doctors who prescribe testosterone to women currently have limited options. Some use testosterone products approved for men and adjust the dose for female patients. Others may use compounded formulations.

This can create practical difficulties.

A product specifically developed and approved for women could potentially provide standardized dosing instructions, clearer labeling and specific guidance for monitoring patients. It could also provide more information about appropriate patient populations and potential risks.

Dr Diana Tordoff of Stanford has highlighted the importance of having treatment options specifically developed for women, according to reporting by The Independent.

The absence of a dedicated FDA-approved product does not mean physicians cannot prescribe testosterone. Rather, it means that clinicians and patients must navigate a treatment landscape in which products may not have been specifically evaluated and labeled for the intended female use.

What are the potential risks?

Testosterone is a biologically active hormone, and taking too much can produce unwanted effects.

Higher exposure can contribute to acne and increased facial or body hair. Other effects, including changes in the voice and hair loss, may be difficult or impossible to reverse.

Doctors also consider a patient’s medical history when deciding whether testosterone is appropriate. Women with a history of certain hormone-sensitive cancers may require particular caution.

Long-term safety remains another major question.

Researchers continue to investigate how testosterone could affect cardiovascular health, breast health and other outcomes when used by women over extended periods.

The FDA has previously considered testosterone for female use on multiple occasions, according to experts cited in The Independent. A recurring concern has been the availability of sufficient long-term safety evidence.

What about testosterone and heart health?

The safety discussion also comes against the backdrop of changes to testosterone labeling for men.

The FDA removed a boxed warning concerning increased cardiovascular risk from certain testosterone products for men following reviews of post-marketing evidence. However, testosterone products continue to carry warnings concerning increased blood pressure.

These developments are relevant to the broader discussion, but evidence from men cannot automatically be applied to women.

Women and men can respond differently to hormones, and the appropriate dose and treatment goals may also differ. This is one reason researchers are seeking studies specifically involving menopausal women.

Research is still underway

New research could help address some of the unanswered questions.

Researchers at Stanford are conducting the MIX-T pilot study, which is examining the effects of low-dose testosterone on vaginal health and the vaginal microbiome in postmenopausal women. Results are expected to provide additional information about possible effects in this area.

Meanwhile, countries including the United Kingdom, Australia, New Zealand and South Africa have approved or licensed testosterone products specifically for female patients.

The existence of these products provides another point of reference for US regulators, although regulatory decisions can differ between countries because approval standards, available evidence and healthcare systems vary.

What should women know?

The growing interest in testosterone does not mean that every menopausal woman needs testosterone therapy.

For women experiencing sexual-health concerns, treatment decisions should begin with an assessment of the underlying problem. Menopause, medications, relationship factors, mental health, sleep problems and other medical conditions can all affect sexual desire and wellbeing.

Other FDA-approved treatments are also available for certain patients with HSDD, including non-testosterone medications such as Addyi and Vyleesi.

The FDA’s review could ultimately help clarify where testosterone fits into this wider range of treatments.

For now, the central issue is not simply whether testosterone works. It is determining which women may benefit, what dose should be used, how treatment should be monitored and what the long-term risks may be.

As demand for menopause care continues to grow, the FDA’s examination could contribute to a clearer evidence base for doctors and patients.

Source

The US Food and Drug Administration and medical experts at Stanford and Mayo Clinic.

Medical disclaimer

This article is intended for general informational purposes only and does not constitute medical advice, diagnosis or treatment. Testosterone therapy can have risks and may not be appropriate for everyone. Anyone considering hormone therapy should discuss their symptoms, medical history, medications and treatment options with a qualified healthcare professional. Evidence and regulatory guidance can change as new research becomes available.